Basics |
Seres Therapeutics, Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company which is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics.
|
IPO Date: |
June 26, 2015 |
Sector: |
Healthcare |
Industry: |
Biotech |
Market Cap: |
$169.49M |
Activated in VL: |
True |
Average Daily Range |
Avg Daily Range: |
$0.37 | 3.70%
|
Avg Daily Range (30 D): |
$0.70 | 4.58%
|
Avg Daily Range (90 D): |
$0.52 | 4.54%
|
Institutional Daily Volume |
Avg Daily Volume: |
1.04M |
Avg Daily Volume (30 D): |
.1M |
Avg Daily Volume (90 D): |
.1M |
Trade Size |
Avg Trade Size (Sh.): |
167 |
Avg Trade Size (Sh.) (30 D): |
74 |
Avg Trade Size (Sh.) (90 D): |
86 |
Institutional Trades |
Total Inst.Trades: |
1,289 |
Avg Inst. Trade: |
$1.88M |
Avg Inst. Trade (30 D): |
$.76M |
Avg Inst. Trade (90 D): |
$.76M |
Avg Inst. Trade Volume: |
.01M |
Avg Inst. Trades (Per Day): |
1 |
Market Closing Trades |
Avg Closing Trade: |
$2.2M |
Avg Closing Trade (30 D): |
$.6M |
Avg Closing Trade (90 D): |
$.6M |
Avg Closing Volume: |
12.51K |
|
|
Financials |
|
TTM |
Q2 2025 |
Q1 2025 |
Basic EPS
|
$1.94
|
$-2.27
|
$3.76
|
Diluted EPS
|
$1.95
|
$-2.27
|
$3.75
|
Revenue
|
$ M
|
$ M
|
$ M
|
Gross Profit
|
$
|
$
|
$
|
Net Income / Loss
|
$ 85.97M
|
$ -19.86M
|
$ 32.68M
|
Operating Income / Loss
|
$ -110.12M
|
$ -24.88M
|
$ -27.24M
|
Cost of Revenue
|
$
|
$
|
$
|
Net Cash Flow
|
$ -27.06M
|
$ -13.47M
|
$ 28.06M
|
PE Ratio
|
9.93
|
|
|
Splits |
Apr 22, 2025:
1:20
|
|
|
|